Business Standard

Cipla hits 52-wk high on launch of generic remdesivir for Covid-19 patients

Remdesivir is the only USFDA approved emergency use authorization treatment in severe (hospitalised) Covid-19 patients.

Cipla hits 52-wk high on launch of generic remdesivir for COVID-19 patients
Premium

Cipla will commercialise remdesivir through its own facilities and partnered sites

SI Reporter Mumbai
Shares of Cipla rallied 9 per cent on Monday to hit a fresh 52-week high of Rs 696 on the BSE after the company launched the generic version of Gilead Sciences' Remdesivir, lyophilized powder for injection, 100 mg under its brand name 'Cipremi'.

Remdesivir is the only United States Food and Drug Administration (USFDA) approved emergenecy use authorization (EUA) treatment in severe (hospitalised) Covid-19 patients.

In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called 'Cipremi'. The company recently received the Drug Controller General of India

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 22 2020 | 11:08 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com